# The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

> **NCT05035589** · — · COMPLETED · sponsor: **Sciberras, Stephen M.D.** · enrollment: 100 (actual)

## Conditions studied

- COVID-19 Pneumonia
- ARDS

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05035589
- **Lead sponsor:** Sciberras, Stephen M.D.
- **Sponsor class:** INDIV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-20
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-11-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035589, "The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05035589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*